William Blair analyst Matt Larew has maintained their bullish stance on STVN stock, giving a Buy rating on July 25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors that highlight Stevanato Group’s strong performance and promising outlook. The company reported a robust second-quarter performance, primarily driven by a shift towards high-value solutions and a reduction in the impact of customer destocking. This positive momentum is further supported by the expansion of new production capacities at their Fishers and Latina facilities.
Despite facing challenges such as foreign exchange headwinds and increased tariffs, Stevanato Group maintained its full-year guidance, showcasing resilience. The company anticipates high single-digit growth in its BDS segment and improved gross and operating margins. These factors, combined with the company’s strategic positioning and market demand, underpin Larew’s confidence in the stock’s potential, leading to the Buy rating.
According to TipRanks, Larew is an analyst with an average return of -6.8% and a 38.60% success rate. Larew covers the Healthcare sector, focusing on stocks such as 908 Devices, AptarGroup, and Maravai Lifesciences Holdings.
In another report released on July 25, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $31.00 price target.